Growing a world-class precision medicine industry - the Australian Precision Medicine Enterprise

Presented by:
Prof Gary Egan and Dr Maggie Aulsebrook, Monash Biomedical Imaging
Daniel Bucki-Smith, Global Medical Solutions (GMS)
Dr David Cade and Dr Jyoti Arora, Telix Pharmaceuticals


Monash Biomedical Imaging is part of the new $71.2 million Australian Precision Medicine Enterprise (APME) facility, which will deliver large-scale development and manufacturing of precision medicines and theranostic radiopharmaceuticals for industry and research. The APME is a collaboration between Monash University, Global Medical Solutions Australia, and Telix Pharmaceuticals.

A key feature of the APME project is a high-energy cyclotron with multiple production clean rooms, which will be located on the Monash Biomedical Imaging (MBI) site in Clayton. This strategic co-location will facilitate radiochemistry, PET and SPECT research and clinical use of theranostic (therapeutic and diagnostic) radioisotopes produced on-site.

In this webinar, MBI’s Professor Gary Egan and Dr Maggie Aulsebrook explain how the APME will secure Australia’s supply of critical radiopharmaceuticals, build a globally competitive Australian manufacturing hub, and train scientists and engineers for the Australian workforce. They are joined by Daniel Bucki-Smith frm Global Medical Solutions (GMS) along with Dr David Cade and Dr Jyoti Arora, Telix Pharmaceuticals

Together, they will cover the APME’s state-of-the-art 30 MeV and 18-24 MeV cyclotrons and radiochemistry facilities, as well as the services that will be accessible to students, scientists, clinical researchers, and pharmaceutical companies in Australia and around the world.